Evaluation of the effect of omega3 on pruritus in patients under peritoneal dialysis

Evaluation of the effect of omega3 on pruritus score in patients under peritoneal dialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138808202370N5

Enrollment

Registered

2012-01-22

Start date

2009-08-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pruritus in peritoneal Patients. End-stage renal disease

Interventions

Intervention 1: cap omega3 1000 mg TDS. Intervention 2: placebo TDS.

Treatment - Drugs

Placebo

cap omega3 1000 mg TDS

placebo TDS

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being under maintenance dialysis for at least one month; Not being under other drug treatment for pruritus; Having pruritus for at least 8 wk; No sensitivity to omega3; Volunteer to participate. Exclusion criteria: Non compliance with drug; Renal transplantation before end of therapy; anemia (Hb300 eq/ml or phosphorus >7mg/dl); PT & INR rising.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease in Pruritus Score. Timepoint: every 2 week. Method of measurement: visual Analog scale.	—

Secondary

Measure	Time frame
Coagulopathy. Timepoint: every month. Method of measurement: PT and INR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mojgan Mortazavi

Isfahan University of Medical Sciences

m_mortazavi@med.mui.ac.ir+98 311625555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026